Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy.

被引：0
|
作者：
Ali, S. M.
Esteva, F. J.
Fornier, M.
Gligorov, J.
Harris, L.
Kostler, W. J.
Luftner, D.
Pichon, M. F.
Tse, C.
Lipton, A.
机构：
[1] Penn State Hershey Med Ctr, Hershey, PA USA
[2] Lebanon VAMC, Lebanon, PA USA
[3] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[5] Tenon Hosp, Paris, France
[6] Yale Univ, New Haven, CT 06520 USA
[7] Univ Hosp Vienna, Vienna, Austria
[8] Humboldt Univ, Berlin, Germany
[9] Biol Specialiste Ctr Lutte Contre, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3S / 3S
页数：1
相关论文
共 50 条
  • [21] Serum Her-2/neu level predicts disease stage and outcome in men with prostate cancer
    Taneja, SS
    Clute, M
    Shuch, B
    Cheli, CD
    Ghani, F
    Osman, I
    JOURNAL OF UROLOGY, 2004, 171 (04): : 441 - 441
  • [22] Clinical value of serum HER-2/neu testing
    Luefner, D.
    Possinger, K.
    TUMOR BIOLOGY, 2007, 28 : 22 - 22
  • [23] Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification
    Arnould, Laurent
    Arveux, Patrick
    Couturier, Jerome
    Gelly-Marty, Marion
    Loustalot, Catherine
    Ettore, Francette
    Sagan, Christine
    Antoine, Martine
    Penault-Llorca, Frederique
    Vasseur, Berangere
    Fumoleau, Pierre
    Coudert, Bruno P.
    CLINICAL CANCER RESEARCH, 2007, 13 (21) : 6404 - 6409
  • [24] Serum HER-2/neu levels in clinical studies with lapatinib in HER-2/neu positive breast cancer
    Maltzman, J.
    Blackwell, K.
    Stein, S.
    Martin, A.
    Westland, R.
    Burstein, H.
    Gomez, H.
    Gartner, N.
    Platek, G.
    Newmiller, M.
    Lipton, A.
    Carney, W. P.
    CLINICAL CHEMISTRY, 2008, 54 (06) : A130 - A130
  • [25] Chromosome 17 polysomy and Her-2/neu status in metastatic breast cancer patients indicated to trastuzumab therapy.
    Hajduch, M
    Trojanec, R
    Bouchalova, K
    Kolar, Z
    Petrakova, K
    Cwiertka, K
    Svoboda, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 857S - 857S
  • [26] HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy
    Pectasides, D
    Gaglia, A
    Arapantoni-Dadioti, P
    Bobota, A
    Valavanis, C
    Kostopoulou, V
    Mylonakis, N
    Karabelis, A
    Pectasides, M
    Economopoulos, T
    ANTICANCER RESEARCH, 2006, 26 (1B) : 647 - 653
  • [27] The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy
    Lee, Jung Sun
    Son, Byung-Ho
    Ahn, Sei Hyun
    JOURNAL OF BREAST CANCER, 2012, 15 (02) : 189 - 196
  • [28] Comparison of serum HER-2/neu between trastuzumab-based regimen and anthyracycline-based regimen during neoadjuvant chemotherapy in advanced primary breast cancer
    Lee, J.
    Min, W.
    Kim, S.
    Son, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer
    Gonzalez-Angulo, Ana M.
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    ONCOLOGIST, 2006, 11 (08): : 857 - 867
  • [30] PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer
    Gschwantler-Kaulich, Daphne
    Tan, Yen Y.
    Fuchs, Eva-Maria
    Hudelist, Gernot
    Koestler, Wolfgang J.
    Reiner, Angelika
    Leser, Carmen
    Salama, Mohamed
    Attems, Johannes
    Deutschmann, Christine
    Zielinski, Christoph C.
    Singer, Christian F.
    PLOS ONE, 2017, 12 (03):
12345